These days, you can't have a conversation about AI in life sciences without someone invoking "human-in-the-loop." It's become so expected that leaving it out feels like a red flag—a signal that AI governance hasn't been fully considered.

The problem isn't the phrase itself. It’s what organizations think it means.

When most pharma teams say human-in-the-loop, what they actually have is a human somewhere in the process. That's not an AI governance strategy. And if that's the full extent of your AI oversight, your pilot probably isn't making it to production.

Why the Phrase Has Become a Comfort Blanket

The concept of human-in-the-loop actually came about long before AI, originating with Norbert Wiener in the 1940s and his work Cybernetics: Or Control and Communication in the Animal and the Machine. He identified the role humans could play in controlling intelligent systems in military and aerospace applications during the Cold War.

Since then, the term has expanded to cover almost anything: human approval before action, data labeling, collaborative decision-making, output review. As long as a person touches the process at some point, it qualifies. Which is exactly the problem.

A human approving AI output is not the same as a human controlling it. In regulated environments, where a medical information response can affect prescribing decisions, patient safety documentation, or adverse event reporting, that distinction matters.

AI governance built on the assumption that review equals control will fail the moment volume, complexity, or regulatory scrutiny increases.

The Systemic Error Problem in AI for Medical Information

Humans make mistakes. AI makes mistakes too. But the tolerance for AI error is fundamentally different—not just because we expect more from technology, but because of how those errors scale.

When a person makes an error in medical information, it affects one output. When an AI model carries a bias, a blind spot, or worse, begins hallucinating, it affects every output simultaneously, at volume, with no natural ceiling.

That changes the entire error-rate conversation. A 0.5% failure rate may sound acceptable, until you multiply it by ten thousand HCP inquiries.

In medical information, the stakes compound. A response that mischaracterizes an off-label use, an interaction risk, or a dosage threshold isn't just a documentation error. It has downstream consequences for the clinicians relying on it and, ultimately, for patients.

This is why "a human reviewed it" isn't governance. It's an assumption that the human caught the problem, had enough context, and had the time to evaluate it properly.

What AI Governance for Medical Information Looks Like

The real question isn't whether there's a human in the loop. It's what that human can actually do, and whether they’re equipped to do it.

Effective governance in AI-enabled medical information functions has a few non-negotiables:

1. Start with defined accountability at every stage
   From data inputs to model training to output review, all with a clear audit trail in case of regulatory scrutiny.
   
2. Define clear roles and expectations
   Every AI project needs someone who not only owns the guardrails but can change them depending on output.
   
3. Ensure you’re tiering your use cases by risk
   Governance challenges vary. Questions about availability generally pose lower risks than those concerning dosage or safety.
   
4. Build trust cross-functionally
   For AI to scale beyond medical information, it must work with quality, regulatory, and compliance functions—not operate in isolation. A one-time sign off does little; sustained, system-level governance creates the biggest impact.

The AI Governance Questions Most Medical Information Teams Haven’t Asked (Yet)

Before any implementation, it's worth taking stock of where your organization actually stands on data quality, process maturity, and risk appetite. These questions aren't meant to slow things down; they're meant to keep you from building something that looks good in a pilot and falls apart in production.

• What may AI do in medical information workflows? What must it never do?
• How will we detect when output quality drifts—not just immediately after launch, but six months out?
• If investigated tomorrow, what would our audit trail actually show?
• Who owns AI governance end-to-end, and do they have the authority to act on what they find?
• How are we validating that the AI's responses align with current medical and regulatory standards beyond internally approved content?
• What happens when a high-risk query falls into a gray area the model wasn't trained for?
• Do clinicians or HCPs receiving AI-assisted responses know they are? Should they?
• How does our governance model account for post-market label changes, new safety signals, or updated clinical guidelines?

The Bottom Line

AI governance in life sciences isn't a checklist. It's the difference between a program that survives scrutiny and one that gets quietly shut down after the first audit.

The organizations getting this right aren't the ones that moved fastest. They're the ones that built internal trust early—with quality, compliance, and regulatory—and expanded from there.

That foundation is what turns a successful pilot into a scalable program.